ArticleNeuro-oncology practice2025

Temozolomide chemotherapy for patients with newly diagnosed glioblastoma in the CENTRIC EORTC 26071-22072 and CORE trials: Does time of administration matter?

Marjolein Geurts et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.